Health economic evaluation of Magtrace and Sentimag
TLV is performing a health economic evaluation of the medical devices Magtrace and Sentimag, a system for detection of sentinel lymph nodes in breast cancer surgery.
Magtrace/Sentimag can replace current standard methods for sentinel lymph node detection i.e. liquids containing radioactive isotopes in combination with blue dye. The products are intended for clinically node negative breast cancer patients in need of a sentinel lymph node biopsy during surgery.
TLV’s preliminary timeline is to conduct the assessment during autumn 2022.
The health economic evaluation will be presented to the MTP Council. The MTP council issues recommendations for use based on TLV’s health economic evaluation as well as other available information.
- 18 May 2022